



Please type a plus sign (+) inside this box → [ + ]

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	10/628,432
		Filing Date	July 29, 2003
		First Named Inventor	C. J. CORCORAN <i>et al.</i>
		Group Art Unit	1656
		Examiner Name	William W. Moore
Total Number of Pages in This Submission	7	Attorney Docket Number	031896-036000 (AM101066)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supp. Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s):  <b>PTO Form-1449 citing two (2) U.S. patent documents, three (3) foreign patent documents, forty (40) non-patent literature documents and one (1) International Search Report.</b>
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-036000) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Raymond Van Dyke, Registration No. 34,746 Nixon Peabody LLP 409 9 <sup>th</sup> Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	July 5, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.	
July 5, 2005 Date	_____ Signature



Docket No. 031896-036000

(AM101066)

Patent

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re* Patent Application of: )  
Christopher J. CORCORAN *et al.* ) Art Unit: 1656  
Serial No.: 10/628,432 ) Examiner: William W. Moore  
Filed: July 29, 2003 ) Confirmation No: 5325  
For: MODIFIED ADAMTS4 MOLECULES )  
AND METHOD OF USE THEREOF )

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. § 1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, copies of each cited foreign patent documents and other non-patent literature documents are enclosed. However, in accordance with the Official Gazette Notice dated August 5, 2003, copies of each cited U.S. patent documents are not included with this Supplemental Information Disclosure Statement.

The cited documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).


In addition, Applicants respectfully note that one (1) of the cited references on the Form PTO-1449 constitutes an entire book, *i.e.*, Harlow and Lane, and a full copy of the more general material will be forwarded to the Examiner upon request.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached Form PTO-1449. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing, which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

Date: July 5, 2005

By:   
Raymond Van Dyke  
Registration No. 34,746

NIXON PEABODY LLP  
Suite 900  
401 9<sup>th</sup> Street, N.W.  
Washington, D.C. 20004-2128  
Telephone: (202) 585-8000  
Facsimile: (202) 585-8080



Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<i>Complete if Known</i>		
				Application Number		10/628,432
				Filing Date		July 29, 2003
				First Named Inventor		C. J. CORCORAN <i>et al.</i>
				Art Unit		1656
				Examiner Name		William W. Moore
Sheet	1	of	4	Attorney Docket Number		031896-036000 (AM101066)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		U.S. - 4,419,446	12-06-1983	HOWLEY <i>et al.</i>	
		U.S. - 4,816,567	03-28-1989	CABILLY <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		EP 0177343 A1	04-19-1985	BOCHNER <i>et al.</i>		
		EP 123289 A2	10-31-1984	BRAKE <i>et al.</i>		
		WO 86/00639 A1	01-30-1986	CLARK <i>et al.</i>		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		AHMED, K. M. <i>et al.</i> , Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer, <i>Cancer Lett.</i> , 180(2):159-163, 2002	
		AHMED, K. M. <i>et al.</i> , Genetic variations of the midkine (MK) gene in human sporadic colorectal and gastric cancers, <i>Int. J. Mol. Med.</i> , 6(3):281-287, 2000	
		ARIDOME, K. <i>et al.</i> , Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas, <i>Br. J. Cancer</i> , 78(4):472-477, 1998	
		BRANDT, K.D. and MANKIN, H.J., Pathogenesis of Osteoarthritis, in "Textbook of Rheumatology," Kelly, W.N., Harris, E.D., Ruddy, S., and Sledge, C.B. (eds), W.B. Saunders Company, Philadelphia, PA, pp. 1355-1373, 1993	
		CLARKSON, T. <i>et al.</i> , Making antibody fragments using phage display libraries, <i>Nature</i> , 352:624-628, 1991	
		FLANNERY, C.R. <i>et al.</i> , Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage, <i>J. Biol. Chem.</i> , 267(2):1008-1014, 1992	
		FOSANG, A.J. <i>et al.</i> , Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan, <i>Biochem. J.</i> , 304 ( Pt 2):347-351, 1994	
		GETHING, M.J. and SAMBROOK, J., Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene, <i>Nature</i> , 293(5834):620-625, 1981	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>		
				Application Number		10/628,432
				Filing Date		July 29, 2003
				First Named Inventor		C. J. CORCORAN <i>et al.</i>
				Art Unit		1656
				Examiner Name		William W. Moore
Sheet	2	Of	4	Attorney Docket Number		031896-036000 (AM101066)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>4</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HARLOW, E. and LANE, D., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988)	
		HARRIS, W.J., Production of humanized monoclonal antibodies for <i>in vivo</i> imaging and therapy, <i>Biochem. Soc. Trans.</i> , 23(4):1035-1038, 1995	
		IKEMATSU, S. <i>et al.</i> , Serum midkine levels are increased in patients with various types of carcinomas, <i>Br. J. Cancer</i> , 83(6):701-706, 2000	
		KANAME, T. <i>et al.</i> , The expression of truncated MK in human tumors, <i>Biochem. Biophys. Res. Commun.</i> , 219(1):256-260, 1996	
		KADOMATSU, K., Recent progress of midkine research on cancer, <i>Nippon Rinsho</i> , 58(6):1337-1347, 2000	
		KOHLER, G. and MILSTEIN, C., Continuous cultures of fused cells secreting antibody of predefined specificity, <i>Nature</i> , 256(5517):495-497, 1975	
		LAEMMLI, U.K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4, <i>Nature</i> , 227(5259):680-685, 1970	
		LEWIS, A.P. and CROWE, J.S., Generation of humanized monoclonal antibodies by 'best fit' framework selection and recombinant polymerase chain reaction, <i>Year Immunol.</i> , 7:110-118, 1993	
		Li, X. <i>et al.</i> , Differential protein profile in the ear-punched tissue of regeneration and non-regeneration strains of mice: a novel approach to explore the candidate genes for soft-tissue regeneration, <i>Biochim. Biophys. Acta</i> , 1524(2-3):102-9, 2000	
		Li, X. <i>et al.</i> , Analysis of gene expression in the wound repair/regeneration process, <i>Mamm. Genome</i> , 12(1):52-59, 2001	
		LOHMANDER, L.S. <i>et al.</i> , The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis, <i>Arthritis Rheum.</i> , 36(9):1214-1222, 1993	
		MACLEAN, C.H. <i>et al.</i> , Costs attributable to osteoarthritis, <i>J. Rheumatol.</i> , 25(11):2213-2218, 1998	
		MANIATIS, T. <i>et al.</i> , Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 387-389, 1982	
		MARKS, J.D., By-passing immunization. Human antibodies from V-gene libraries displayed on phage, <i>J. Mol. Biol.</i> , 222(3):581-597, 1991	
		MIYASHIRO, I. <i>et al.</i> , Expression of truncated midkine in human colorectal cancers, <i>Cancer Lett.</i> 106(2):287-291, 1996	
		MORRISON, S. L. and SCHLOM, J., Recombinant chimeric monoclonal antibodies, in S. A. Rosenberg (ed.), <i>Important Advances in Oncology 3</i> , Lippincott, Philadelphia, PA, 1990	
		OAKLEY, B.R. <i>et al.</i> , A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels, <i>Anal. Biochem.</i> , 105(2):361-363, 1980	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<i>Complete if Known</i>			
				Application Number		10/628,432	
				Filing Date		July 29, 2003	
				First Named Inventor		C. J. CORCORAN <i>et al.</i>	
				Art Unit		1656	
				Examiner Name		William W. Moore	
Sheet	3	Of	4	Attorney Docket Number		031896-036000 (AM101066)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		PAUL, S. <i>et al.</i> , Detection of truncated midkine in Wilms' tumor by a monoclonal antibody against human recombinant truncated midkine, <i>Cancer Lett.</i> , 163(2):245-251, 2001		
		PAUL, S. <i>et al.</i> , Molecular cloning, expression and purification of truncated midkine and its growth stimulatory activity on Wilms' tumor (G401) cells, <i>Cancer Lett.</i> , 163(2):239-244, 2001		
		PRESTA, L., Humanized Monoclonal Antibodies, in <i>Annual Reports in Medicinal Chemistry</i> , Academic Press, 1994		
		ROBERTS, S. <i>et al.</i> , Matrix turnover in human cartilage repair tissue in autologous chondrocyte implantation, <i>Arthritis Rheum.</i> , 44(11):2586-2598, 2001		
		SANDY, J.D. <i>et al.</i> , Analysis of the catabolism of aggrecan in cartilage explants by quantitation of peptides from the three globular domains, <i>J. Biol. Chem.</i> , 266(13):8198-8205, 1991		
		SANDY, J.D. <i>et al.</i> , The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain. <i>J. Clin. Invest.</i> , 89(5):1512-1516, 1992		
		TOWBIN, H. <i>et al.</i> , Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications, <i>Proc. Natl. Acad. Sci. U S A.</i> , 76(9):4350-4354, 1979		
		WINTER, G. and MILSTEIN, C., Man-made antibodies, <i>Nature</i> , 349(6307):293-299, 1991		
		International Search Report mailed March 2, 2004, corresponding with International Application PCT/US2003/23483, 4 pages		
		NCBI Annotation Project, XP_123829.midkine [Mus musc...[gi:20839708], National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;val=20839708">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;val=20839708</a> , 16-MAY-2002		
		Uehara, K. <i>et al.</i> , BAA01457.midkine [Homo sapiens...[gi:219929], National Center for Biotechnology Information, 8600 Rockville Pike, Bethesda, MD 20894, <a href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;val=219929">http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&amp;val=219929</a> , PRI 29-May-1992		
		JAX Mice MRL/MpJ Product Specification, Stock No. 000486, The Jackson Laboratory, Bar Harbor, ME, pages 1-5, March 19, 2002		
		JAX Mice B6.MRL-Tnfrsf6 <sup>lpr</sup> Product Specification, Stock No. 000482, The Jackson Laboratory, Bar Harbor, ME, pages 1-4, March 19, 2002		
		ZHANG, N. and DEUEL, T.F., Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors, <i>Curr. Opin. Hematol.</i> 6(1):44-50, 1999.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>			
				Application Number		10/628,432	
				Filing Date		July 29, 2003	
				First Named Inventor		C. J. CORCORAN <i>et al.</i>	
				Art Unit		1656	
				Examiner Name		William W. Moore	
Sheet	4	Of	4	Attorney Docket Number		031896-036000 (AM101066)	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		HAYNES, H. and RUMSBY, M., The pleiotropin/midkine family of cytokines: role in glial-neuronal signaling, <i>Prog. Brain Res.</i> , 132:313-324, 2001	
		MURAMATSU, T., Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation, <i>Int. J. Dev. Biol.</i> , 37(1):183-188, 1993	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.